Izabela Amélia Marques Andrade

Izabela Amélia Marques Andrade

Auto-generated profile, based on publicly available information

Izabela Amélia Marques Andrade

Department of Clinical and Experimental Oncology, Federal University of São Paulo (UNIFESP), São Paulo, Brazil

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 August 2026 in Science Advances
Verified
Journal Article
Open access
ISIzadora Souza
Izadora Souza
IAIzabela Amélia Marques Andrade
Izabela Amélia Marques Andrade
FFFlorencio Porto Freitas
Florencio Porto Freitas
Ana Beatriz da Silva TeixeiraAna Beatriz da Silva Teixeira
Ana Beatriz da Silva Teixeira
MRMaria Carolina Clares Ramalho
Maria Carolina Clares Ramalho
JAJosé Pedro Friedmann Angeli
José Pedro Friedmann Angeli
Modulating the intracellular labile iron pool (LIP) has emerged as a promising strategy to induce ferroptosis in cancer cells, offering a way to overcome resistance to apoptosis-based therapies. One of the main contributors to LIP is heme catabolism mediated by heme oxygenase-1 (HMOX1), which promotes ferroptosis sensitivity by releasing free iron. Beyond its role as an iron donor, heme can influence diverse proteins and signaling pathways that drive tumor progression, but how heme regulates ferroptosis remains poorly understood. Here, we uncover a paradoxical, protective function of heme in the absence of HMOX1 activity. When HMOX1 is inactive, heme becomes stabilized, leading to ferritin up-regulation, suppression of ferroptosis, and rescue of cell death induced by both pharmacological and genetic inhibition of GPX4. Our findings reveal an unrecognized heme-HMOX1-ferritin axis that controls ferroptosis sensitivity. Targeting this pathway may offer a new therapeutic strategy to modulate ferroptosis in cancer.